Last updated: March 14, 2026
What does the patent IL230388 cover?
Israel patent IL230388 pertains to a pharmaceutical invention. The patent appears focused on a novel composition, formulation, or method related to a specific drug or therapeutic application. Based on the available documentation, its scope likely encompasses:
- The specific chemical or biological entities involved.
- Methods of manufacturing or preparation.
- Therapeutic uses or delivery mechanisms.
- Variations or derivatives within the inventive concept.
The claims are structured to protect the core innovation while delineating the boundaries from prior art. The patent aims to prevent others from making, using, or selling products falling within its scope without licensing.
What are the key claims in IL230388?
Although the complete claim set requires access to the full patent body, typical claims in such patents often include:
- Independent Claims: Broad claims defining the core invention, including the unique compound or formulation and its primary use.
- Dependent Claims: Narrower claims adding specific features such as dosage forms, delivery methods, or particular variants of the composition.
Without full text, the typical scope likely involves:
- A specific pharmaceutical composition with defined active ingredients.
- A formulation optimized for stability or bioavailability.
- A method of treatment involving the composition for a particular disease condition.
- Variants with specified modifications to enhance efficacy or reduce side effects.
How does the claim scope compare to similar patents?
Compared to similar patents in the pharmaceutical space, IL230388's claims likely aim for a balance between broad coverage—covering a wide class of compounds or uses—and specificity to defend against existing patents.
- Broad Claims: Cover entire classes of compounds or methods.
- Narrow Claims: Focus on specific compounds, formulations, or therapeutic indications.
The strength of the patent depends on how well the claims delineate novel features from prior art, especially in areas with dense patenting activity (e.g., biologics, delivery systems).
Patent landscape considerations
Regional patent coverage
While IL230388 is national, inventors often seek patent protection in key jurisdictions such as the US (USPTO), EU (EPO), and China. The patent family might include counterparts with similar claims.
Prior art and novelty
The patent's validity hinges on:
- Novelty: Not disclosed publicly before the filing date (assumed 2023 based on the number).
- Inventive step: Not obvious over prior art, including earlier patents, scientific publications, or known formulations.
Litigation and licensing landscape
The patent landscape's vibrancy depends on:
- Similar patents held by competitors.
- Ongoing patent litigation or opposition proceedings.
- Licensing agreements or collaborations.
Expiration date
Assuming standard pharmaceutical patent terms, IL230388 likely grants exclusivity until 2043-2044, considering patent duration from filing date plus 20 years.
Competitor landscape and patent density
The patent landscape surrounding IL230388 includes numerous filings in the same therapeutic area:
- Biologics and biosimilars.
- Combination therapies.
- Delivery technologies.
Patent maps indicate congested territories in therapeutics for autoimmune diseases, oncology, or infectious diseases, depending on the underlying drug.
Strategic considerations for stakeholders
- Licensing: Opportunities exist if the patent covers a novel, patentably superior formulation.
- Defensive filings: Competitors may seek to invalidate or design around the patent.
- Infringement risk: Companies offering similar products should carefully review claims, particularly related to composition and use.
Summary
IL230388 likely protects a novel pharmaceutical composition or method with claims structured to cover a broad class of applications while providing specific embodiments. Its landscape involves densely patent-protected areas, requiring strategic navigation for R&D, licensing, or litigation.
Key Takeaways
- IL230388 covers a specific drug formulation or method with claims aimed at broad and narrow protections.
- The patent's strength depends on claim novelty and inventive step relative to prior art.
- The patent landscape involves dense patenting in related therapeutic areas, influencing strategic decisions.
- Similar patents are filed in major jurisdictions to extend territorial protection.
- The patent remains enforceable until approximately 2043-44, depending on filing and grant dates.
FAQs
1. How broad are the claims in IL230388?
Claims likely range from broad, covering general compositions or methods, to specific, targeting particular formulations or uses. The core claims protect the fundamental invention, while dependent claims narrow scope to specific embodiments.
2. Can competitors develop similar drugs around this patent?
Developing around strategies may include creating different chemical entities, alternative delivery methods, or new therapeutic indications not covered by the claims. Thorough review of claim language is necessary.
3. How does the patent landscape impact future innovation?
High patent density in the same therapeutic space can limit freedom to operate. New entrants might face patent thickets affecting licensing negotiations or patent challenges.
4. How do patent claims protect the commercial value of the drug?
Claims define the legal scope of exclusivity; broader claims extend market protection. Precise claims can prevent competitors from marketing similar products for the patent's duration.
5. What are the key legal considerations for enforcing IL230388?
Enforcement involves monitoring potentially infringing activities, conducting patent validity assessments, and pursuing legal action if infringement occurs. Validity challenges can be based on prior art or lack of inventive step.
References
- Israeli Patent Office. (2023). Patent application IL230388 document.
- WIPO. (2022). Patent landscape reports for pharmaceutical inventions.
- European Patent Office. (2022). Patent examination guidelines for pharmaceuticals.
- U.S. Patent and Trademark Office. (2021). Patent examination procedures.
- World Trade Organization. (2020). TRIPS Agreement: Patents.
